2,217 reports of this reaction
3.1% of all DOXYCLYCLINE HYCLATE reports
#1 most reported adverse reaction
DRUG HYPERSENSITIVITY is the #1 most commonly reported adverse reaction for DOXYCLYCLINE HYCLATE, manufactured by Lupin Pharmaceuticals, Inc.. There are 2,217 FDA adverse event reports linking DOXYCLYCLINE HYCLATE to DRUG HYPERSENSITIVITY. This represents approximately 3.1% of all 70,851 adverse event reports for this drug.
Patients taking DOXYCLYCLINE HYCLATE who experience drug hypersensitivity should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DRUG HYPERSENSITIVITY is moderately reported among DOXYCLYCLINE HYCLATE users, representing a notable but not dominant share of adverse events.
In addition to drug hypersensitivity, the following adverse reactions have been reported for DOXYCLYCLINE HYCLATE:
The following drugs have also been linked to drug hypersensitivity in FDA adverse event reports:
DRUG HYPERSENSITIVITY has been reported as an adverse event in 2,217 FDA reports for DOXYCLYCLINE HYCLATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
DRUG HYPERSENSITIVITY accounts for approximately 3.1% of all adverse event reports for DOXYCLYCLINE HYCLATE, making it one of the most commonly reported side effect.
If you experience drug hypersensitivity while taking DOXYCLYCLINE HYCLATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.